Is Roche's Fenebrutinib a Game Changer for Multiple Sclerosis Treatment

Related Articles

Is UCB's $2.2 Billion Bet on Candid Therapeutics a Game Changer for Autoimmune Treatment

3 months ago

Is Bristol Myers Squibb's New Multiple Myeloma Drug a Game Changer

6 months ago

Is Netflix's Strategic Pivot a Game Changer for Investors

5 months ago

A Game Changer for Schizophrenia Treatment? Teva and Medincell's Olanzapine LAI Accepted by FDA

6 months ago

Category

You may also like

Stock News•2 weeks ago

Parkinson's drug developers are betting big on inflammation

Parkinson's drug developers are shifting focus to inflammation as a disease-modifying target, moving beyond the alpha-synuclein approach. This strategic pivot could reshape R&D pipelines and competiti...

BIVI

Share

Stock News•3 weeks ago

Oculis Announces Positive FDA Pre-IND Feedback Supporting Privosegtor Development Strategy for Treatment of Acute Multiple Sclerosis Relapses

Oculis received positive FDA pre-IND feedback supporting Privosegtor's regulatory pathway for acute MS relapses, with a new IND submission planned for Q4 2026. The FDA confirmed existing data can be c...

OCS

Share

Stock News•1 months ago

Can Biogen Score Another Win In Alzheimer's Disease?

Biogen and Ionis' tau-targeting Alzheimer's treatment slowed cognitive decline by 26% over 18 months, potentially adding a new therapy to Biogen's pipeline after its earlier Aduhelm struggles.

BIIB

Share

Stock News•1 months ago

TG Therapeutics Begins Phase II Study With Briumvi in Schizophrenia

TG Therapeutics shares rose after initiating a Phase II study of Briumvi in treatment-resistant schizophrenia, expanding the drug's potential beyond multiple sclerosis.

TGTX

Share